Using Surveys for PMCF Data Collection: Key Strategies to Fulfill EU MDR Clinical Requirements
Post-Market Clinical Follow-Up (PMCF) is no longer a soft recommendation—it is a regulatory imperative under the European Medical Device Regulation (EU MDR 2017/745). According to Annex XIV, Part B, manufacturers are required to proactively and systematically collect clinical data throughout the entire life cycle of their devices. One of the most effective tools to meet these obligations—especially for legacy or high-risk devices—is using surveys for PMCF data collection. This article outlines a fully MDR-aligned methodology for planning, executing, and integrating surveys within the broader post-market surveillance (PMS) and clinical evaluation processes.
PMCF Obligations and the Role of Surveys
The Legal Basis: EU MDR Annex XIV, Part B
PMCF is described as “a continuous process that updates the clinical evaluation.” The regulation stipulates that PMCF shall be used to:
Confirm the safety and performance of the device during its expected lifetime,
Identify previously unknown side-effects,
Monitor the identified risks,
Ensure the continued acceptability of the benefit-risk ratio.
Why Surveys Meet Regulatory Expectations
Surveys, when properly designed, can:
Generate real-world clinical evidence,
Validate safety endpoints for Class IIb and Class III devices,
Capture Patient-Reported Outcomes (PROs) and clinician experiences,
Address clinical data gaps identified during the initial CER (Clinical Evaluation Report).
Types of PMCF Surveys and Their Applications
General Surveys
Intended to gather broader information such as:
Device usability,
Complaint trends,
Procedural consistency.
Useful for devices with lower clinical risk (e.g., Class I, some IIa).
Specific Surveys
Targeted toward measurable clinical endpoints, especially for:
Devices with novel features,
Implantable devices (e.g., ureter stents, orthopedic implants),
High-risk classifications (Class IIb, III).
Example: A PMCF survey for a Class IIb ureter stent includes endpoints such as:
Stenting success rate ≥ 98.8%,
Hematuria incidence < 12.4%,
Stent migration < 2.9%.
Regulatory-Compliant Survey Design: Key Considerations
Define Clinical Objectives
Start with clear alignment to CER safety and performance claims. Each objective should correspond to a clinical benefit or residual risk under scrutiny.
Use the GHTF Clinical Evaluation Guidelines (SG5/N2R8) to support your survey objectives, especially when selecting performance parameters or adverse event thresholds.
Assess Device Risk Classification
Higher-risk devices demand more:
Frequent data collection intervals (e.g., annually),
Rigorous sample size calculations,
Justifiable methodologies using statistical power analysis.
Define the Target Population
Specify:
Demographics,
Indication for use,
Geographic distribution.
Ensure that the population reflects the intended user and patient base as described in the IFU (Instructions for Use).
Select the Right Format and Tools
Regulatory expectations recommend:
Electronic Data Capture (EDC) systems,
Survey platforms with audit trails and GDPR compliance,
Standardized coding systems (e.g., MedDRA, SNOMED CT).
Survey Validation and Testing
Pilot Testing
Pilot surveys with a subset of your target audience to:
Detect ambiguous language,
Evaluate response rates,
Refine question logic.
Use a cross-functional review process involving clinical, regulatory, and human factors experts.
Language and Accessibility
Ensure linguistic validation if surveys are deployed in multiple EU member states. Use plain language and offer multilingual options for both HCP and patient-facing questionnaires.
Data Analysis and Integration into the Technical Documentation
How to Use Survey Data in the CER and PMS
Survey data must be:
Quantified (statistical summaries),
Analyzed against predefined endpoints,
Linked directly to claims made in the IFU and marketing materials.
Include the results in:
Section 6.2 of the Clinical Evaluation Report (Summary of Post-Market Data),
Periodic Safety Update Reports (PSURs) for Class IIb and III,
Risk Management Files (per ISO 14971:2019).
Ensure Traceability
Establish traceability from:
Survey question → Clinical objective → CER section → Risk control → PMS activity.
Document this trail in your PMCF plan (per MDCG 2020-7).
Real-World Case Study: PMCF Survey for Class IIb Ureteral Stent
Clinical Goals
Performance target: ≥ 98.8% procedural success,
Safety targets: Hematuria < 12.4%, Migration < 2.9%.
Survey Design
12-question HCP survey + 8-question patient follow-up,
Conducted via GDPR-compliant EDC system,
Responses linked to anonymized patient records.
Outcome
Targets confirmed with 95% confidence intervals,
Survey cited in CER Update (Rev 3),
Successfully passed Notified Body audit in March 2025.
Common PMCF Survey Pitfalls and How to Avoid Them
| Challenge | Regulatory-Safe Solution |
|---|---|
| Unclear objectives | Map every question to clinical endpoints |
| Low response rates | Limit survey length; offer reminders |
| GDPR non-compliance | Use consent forms; ensure encryption |
| Poor data quality | Use closed questions; pilot test tools |
| Misalignment with CER | Pre-plan integration with safety/performance claims |
Advanced Tips for Enhancing Survey Validity
Use CE-Marked Digital Tools
Where possible, use CE-marked clinical apps or patient follow-up tools for survey administration. This demonstrates a higher level of regulatory diligence.
Involve Clinical Experts Early
Engage clinicians or KOLs during survey design. Their insights ensure clinical relevance and reduce ambiguous question phrasing.
Implement Version Control
Document changes between survey versions and provide justifications in your PMCF Evaluation Report.
FAQs: Regulatory-Centric Clarifications on PMCF Surveys
Are surveys acceptable as clinical evidence under MDR?
Yes, provided they are aligned with Annex XIV Part B and documented in the CER, RMF, and PMS Plan.
Do I need ethics approval?
For patient-facing surveys, likely yes. HCP-only surveys may be exempt depending on jurisdiction.
Can I use the same survey every year?
Only if endpoints, methodology, and population remain unchanged. Version control and justification are necessary.
Are open-ended responses acceptable?
Use cautiously. They are harder to quantify and may not meet statistical reliability standards.
Is a sample size justification mandatory?
Yes. Surveys must be powered to detect statistically relevant trends for the endpoints they aim to validate.
Should surveys be multilingual?
Absolutely. Ensure linguistic validation if devices are marketed in multiple EU regions.
Final Thoughts
In a strict regulatory environment, using surveys for PMCF data collection can be a cost-effective, powerful strategy to maintain CE marking. But this only holds true when those surveys are designed, validated, executed, and documented with the same rigor as clinical trials.
Treat your surveys as part of your device’s clinical evidence—not as supplemental data. With correct alignment to MDR, GSPR, and ISO standards, surveys not only close clinical gaps but also build robust, traceable, and defensible clinical evaluation frameworks.
PS: For more information, subscribe to my newsletter and get access to exclusive content, private insights, and expert guidance on MDR compliance and CE marking:
✌️ Peace,
Hatem Rabeh, MD, MSc Ing
Your Clinical Evaluation Expert & Partner
Follow me for more insights and practical advice!
